Previous 10 | Next 10 |
Voyager Therapeutics (VYGR): Q3 GAAP EPS of $2.27.Collaboration revenue of $117.84M (+476.8% Y/Y).Cash, cash equivalents and marketable debt of of $200M.Press Release For further details see: Voyager Therapeutics reports Q3 results
CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR) today reported its third quarter 2020 financial results, program progress and corporate updates. “During the third quarter, we took important steps to advance our lead programs for Par...
ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. While overall market breadth remains narrow, the Strategy...
Regeneron reports positive outcome for Phase 3 trial of Dupixent. Voyager slumps as FDA puts hold on Huntington’s disease program. Athenex boosts TCT-T cell therapy program with PharmaEssentia collaboration. For further details see: Regeneron Reports Positive ...
20 Gene Therapy Clinical Trials Using the ClearPoint platform. Utilizes Razor / Blades Business Model. Disposables and Biologics ("Blades") revenues up 183% in Q2 2020. Significant Operating Leverage: Past 5 Years SG&A up ~20% while Gross Profit was up Over 300%. Large...
Shares of the clinical-stage gene therapy company Voyager Therapeutics (NASDAQ: VYGR) dropped by as much as 11% in pre-market trading Tuesday morning. The biotech's shares are responding negatively to a regulatory delay for its Huntington's disease candidate, VY-HTT01. After...
Gainers: [[ETH]] +11.8%. [[SOS]] +9.0%. [[DIS]] +5.3%. [[EXC]] +5.1%. [[IVA]] +4.2%.Losers: [[VYGR]] -13.9%. [[HX]] -9.2%. [[IH]] -3.5%. [[CVI]] -2.4%. [[ICLK]] -2.1%. For further details see: ETH, DIS, VYGR and CVI among after-hours movers
The company's Investigational New Drug ((IND)) submission for VY-HTT01 for the treatment of Huntington’s disease has been placed on clinical hold pending the resolution of certain chemistry, manufacturing and controls ((CMC)) matters.Voyager (VYGR) expects specific feedb...
CAMBRIDGE, Mass., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced that it has received feedback from the U.S. Food and Drug Adm...
AXGT has promising gene therapy results in Parkinson's Disease. If future clinical results mimic the early ones, AXGT could have an addressable market of over $7.5 billion. Trading at an enterprise value of $143M, the risk reward ratio is enticing. Nonetheless, investors sho...
News, Short Squeeze, Breakout and More Instantly...
Voyager Therapeutics Inc. Company Name:
VYGR Stock Symbol:
NASDAQ Market:
Voyager Therapeutics Inc. Website:
LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the company will participate in fireside chats at the TD Cowen Genetic Medicines & RNA Summit on June 20, ...
LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment of Nathan Jorgensen, Ph.D., MBA, as Chief Financial Officer (CFO), effective July 8, 2024. Jorgense...
LEXINGTON, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the first participants were dosed in a Phase 1a single ascending dose (SAD) trial of VY-TAU01, an investigation...